Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects with Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
B
Bert O'Neil, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to see if IMC-3C5 is safe to give to patients and to determine the best dose to give.
Description
The purpose of this study is to see if IMC-3C5 is safe to give to patients and to determine the best dose to give.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Solid Tumor
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
20 Nov 2022.
Study ID: 1105005289